← Back to patent-cliff list
Tofersen
Tier C — Watch / tradeTofersen
Ionis Pharmaceuticals Inc
Originator
2023
First approval
-
Expiry (public)
$0.09B ▲
Peak sales
Nucleic acid drug
Type
Targets：SOD
Brand：QALSODY, Qalsody
Indications (approved)：Amyotrophic lateral sclerosis
Regional status
US
Approved
2023-04-25
EU
Approved
2024-05-29
China
Approved
2024-09-26
Japan
Approved
2024-12-27
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Tofersen?
Approved indications include: Amyotrophic lateral sclerosis.
When does the Tofersen patent expire?
No public expiry year is available for Tofersen yet; this page updates once verified.
How do I get a quote for Tofersen intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27